安络化纤丸治疗慢性乙型肝炎肝纤维化的疗效观察

Clinical curative effect of Anluohuaxian capsule on treating patients with chronic hepatitis B and liver fibrosis

目的评价安络化纤丸治疗慢性乙型肝炎肝纤维化的有效性及安全性。方法采用随机开放性临床实验设计。选用慢性乙型肝炎肝纤维化患者72例,随机分配到实验组37例(安络化纤丸每次6克,口服,每天两次,疗程6个月),对照组35例(常规保肝组,疗程6个月)。治疗前后检测肝肾功能、肝纤维化指标(HA、LN、PC-Ⅲ、Ⅳ-C)、血常规、B超。结果实验组血清肝纤维化指标改善优于对照组(P<0.05),实验组治疗后门脉主干内径及脾脏厚度较治疗前有明显缩小(P<0.05)。结论安络化纤丸具有明显的抗肝纤维化作用,是治疗慢性乙型肝炎肝纤维化的非常有效和安全的药物。

Objective To evaluate the clinical efficacy and safety of Anluohuaxian capsule on treating patients with chronic hepatitis B and liver fibrosis. Methods A total of 72 patients with chronic hepatitis B and liver fibrosis were enrolled into this randomized and open clinical study. They were randomly divided into two groups： 37 cases in experimental group and 35 cases in control group. The experimental group were given Anluohuaxian capsule 6.0 g twice a day for six months and the control group were given conventional treatment. Liver and kidney function, blood routine, serum index of liver fibrosis and ultrasound were measured before and after treatment. Results Serum liver fibrosis indexes in experimental group were better than those of control group （P 〈 0.05 ） . Portal vein diameter and thickness of the spleen in experimental group were significantly reduced after treatment （P 〈 0.05） .Conelusions Anluohuaxian capsule is effective and well-tolerated for patients with chronic hepatitis B and liver fibrosis.